Skip to content

Effect of Oat Bran on Bowel Function and Appetite

The Effect of Oat Bran on Bowel Function and Appetite. A Randomized, Double-blind, Placebo-controlled, Cross-over Intervention Study in Healthy Humans.

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03014141
Acronym
OATGUT
Enrollment
0
Registered
2017-01-09
Start date
2018-06-30
Completion date
2019-03-31
Last updated
2018-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Disorder, Functional

Brief summary

The consumption of oat bran fiber also has a significant bulking effect in humans. However, besides fecal bulk, dietary fiber can promote gut health in other ways. Therefore, the purpose of this study is to investigate the effects of oat bran (rich in oat beta-glucan) supplementation on bowel function and appetite.

Detailed description

The study is a randomized, double-blind, placebo-controlled crossover study it involves a total of 8 visits with a 14 day run-in period for total study duration of 84 days. A washout period of 2 weeks will occur in between the 2, 28 day treatment periods. The effects of an oat bran beverage for breakfast on bowel function will be tested after 2 week and 4 weeks of intake.

Interventions

OTHEROat bran (Oatwell 28)

11 g oat bran containing 3.1 gram oat beta-glucan

OTHERMaltodextrin

11 g of Maltodextrin

Sponsors

DSM Nutritional Products, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy male or female between the ages of 18-60 years * Subject has a body mass index of ≥18.5 and ≤30 kg/m2 at screening visit. * Subject is willing to stick to their normal habitual diet excluding the consumption of any unusual high energy-rich or fat-rich meals or prolonged fasting, etc. through the study period. * Subject is willing to maintain their habitual physical activity patterns throughout the study period. * Subject has been weight stable within the last 6 months. * Subject has no health conditions that would prevent him or her from fulfilling the study requirements as judged by the investigator on the basis of medical history and routine laboratory test results. * Low fiber consumer (≤14 g per day) * Subject is willing to follow study procedures and dietary restrictions (ex: stick to habitual diet, refrain from consuming alcohol 24 hours prior to test days).

Exclusion criteria

* History of a gastrointestinal disorder * Lactose intolerant * High fiber consumer (≥15 g per day) * Use of pre-and probiotics in the past 90 days * High protein consumer (i.e. vegetarians or those who follow diets high in protein such as paleo) * History of psychological illness or conditions that may interfere with subjects ability to understand study directions * Use of antibiotics or signs of active systemic infection in the last 6 months. * Subjects who are on hypo/hypercaloric diet aiming for weight loss or weight gain * History or presence of cancer in the prior 2 years (except for non-melanoma skin cancer). * Currently pregnant, lactating or planning to be pregnant during the study period * Regular use of dietary supplements (ex: fish oil, riboflavin, etc.), 90 days prior to study inclusion * Exposure to any non-registered drug product within the last 30 days prior to screening visit * History of or strong potential for alcohol or substance abuse (within 12 months of screening visit). Alcohol abuse is defined as \>60g (men)/40g (women) pure alcohol per day (1.5 L/ 1 l beer resp. 0.75l/0.5l wine). * Allergy or sensitivity to oat bran or any meals or snacks provided * Current smoker or use of tobacco products in the past 90 days * Concurrent or recent participation (30 days) in a dietary intervention trial * Anything in the judgment of the investigator would interfere with the subject's ability to comply with the study (protocol), which might confound the interpretation of the study results, or put the subject at undue risk.

Design outcomes

Primary

MeasureTime frameDescription
Whole gut transit time4 weeksWhole gut transit time is the time required for the passage of 80% of radio-opaque markers (ROM) which are detected by x-ray in the fecal samples collected over the next 5 days after swallowing the ROM.

Secondary

MeasureTime frameDescription
Stool frequency2 weeks and 4 weeksusing a bowel movement diary
Fecal output2 weeks and 4 weeksFecal out is the weight of the fecal samples collected over the 5 days preceding the 2 week and 4 week time point
Percent fecal moisture2 weeks and 4 weeksFecal moisture is determined by freeze drying fecal samples and calculating the percent moisture in the fecal sample
Bristol Stool Score2 weeks and 4 weeksusing Bristol Stool Chart
Fecal pH2 weeks and 4 weeks
Subjective measures of bowel comfort2 weeks and 4 weeksGastrointestinal Quality of life questionnaires (GIQLI)
Gut microbiota2 weeks and 4 weeksUsing 16S ribosomal RNA sequencing techniques
Whole gut transit time2 weeksWhole gut transit time is the time required for the passage of 80% of radio-opaque markers (ROM) which are detected by x-ray in the fecal samples collected over the next 5 days after swallowing the ROM.
Fecal total bile acids2 weeks and 4 weeks
Fecal enzymes2 weeks and 4 weeksfecal beta-glucoronidase
Fecal ammonia2 weeks and 4 weeks
Intestinal gas production2 weeks and 4 weeksusing breath hydrogen production
Appetite2 weeks and 4 weeksAppetite will be measured via visual analogue score (VAS)
Ad libitum energy intake2 weeks and 4 weeksAd libitum energy intake is measured by serving the subject an excess of food
Fecal short chain fatty acids2 weeks and 4 weeksUsing gas chromatography

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026